Tags

Type your tag names separated by a space and hit enter

Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther 2004; 19(4):455-62AP

Abstract

BACKGROUND

Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population.

AIM

To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease.

METHODS

Forty-four patients (male to female ratio, 27 : 17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period.

RESULTS

Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups.

CONCLUSION

Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population.

Authors+Show Affiliations

Department of Medicine, University of Hong Kong, Hong Kong SAR, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14871286

Citation

Wong, W M., et al. "Double-blind, Randomized Controlled Study to Assess the Effects of Lansoprazole 30 Mg and Lansoprazole 15 Mg On 24-h Oesophageal and Intragastric pH in Chinese Subjects With Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 19, no. 4, 2004, pp. 455-62.
Wong WM, Lai KC, Hui WM, et al. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19(4):455-62.
Wong, W. M., Lai, K. C., Hui, W. M., Lam, K. F., Huang, J. Q., Hu, W. H., ... Wong, B. C. (2004). Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 19(4), pp. 455-62.
Wong WM, et al. Double-blind, Randomized Controlled Study to Assess the Effects of Lansoprazole 30 Mg and Lansoprazole 15 Mg On 24-h Oesophageal and Intragastric pH in Chinese Subjects With Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2004 Feb 15;19(4):455-62. PubMed PMID: 14871286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. AU - Wong,W M, AU - Lai,K C, AU - Hui,W M, AU - Lam,K F, AU - Huang,J Q, AU - Hu,W H C, AU - Wong,N Y H, AU - Lam,C L K, AU - Xia,H H X, AU - Chan,A O O, AU - Lam,S K, AU - Wong,B C Y, PY - 2004/2/12/pubmed PY - 2004/4/17/medline PY - 2004/2/12/entrez SP - 455 EP - 62 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 19 IS - 4 N2 - BACKGROUND: Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population. AIM: To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease. METHODS: Forty-four patients (male to female ratio, 27 : 17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period. RESULTS: Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups. CONCLUSION: Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/14871286/Double_blind_randomized_controlled_study_to_assess_the_effects_of_lansoprazole_30_mg_and_lansoprazole_15_mg_on_24_h_oesophageal_and_intragastric_pH_in_Chinese_subjects_with_gastro_oesophageal_reflux_disease_ L2 - https://doi.org/10.1046/j.1365-2036.2004.01846.x DB - PRIME DP - Unbound Medicine ER -